RxDoctor Payments Data

Arun Arora, MD

Critical Care Medicine · Flushing, NYNPI 1154326825

Payments from drug & device makers

$459in general payments, 2019–2025

Across 21 payments — averaging $21.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$125
  • Acadia Pharmaceuticals Inc$73
  • Sunovion Pharmaceuticals Inc.$60
  • Novartis$39
  • Avanir Pharmaceuticals, Inc.$36
  • AstraZeneca$34
  • plus $91 from 4 others

What the payments were for

  • Food & beverage$459100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$459 in reported general payments places this provider in the 65th percentile of 442 critical care medicine providers in New York.

See all critical care medicine providers in New York

Medicare billing

Part B allowed, 2024
$1,307,969
Medicare patients
476
Services billed
10,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban765$236,742
JardianceEmpagliflozin378$121,310
JanuviaSitagliptin Phosphate245$77,040
OtezlaApremilast27$65,414
Risperdal ConstaRisperidone Microspheres57$57,811
InvokanaCanagliflozin106$41,830
EntrestoSacubitril/Valsartan107$37,035
NuedextaDextromethorphan Hbr/Quinidine44$34,720
SantylCollagenase Clostridium Hist.45$30,993
TradjentaLinagliptin107$30,887
XareltoRivaroxaban92$29,829
TrulicityDulaglutide23$24,042
LokelmaSodium Zirconium Cyclosilicate67$20,518
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$18,223
Memantine Hcl471$16,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$39$37,035107 claims
Avanir Pharmaceuticals, Inc.Nuedexta$36$34,72044 claims
AstraZenecaLokelma, Farxiga$34$31,578103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 442 critical care medicine providers in New York.

Other critical care medicine in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →